WaveMan
WaveMan · Company
LQDA · Liquidia Corp
> Search tickers & screens ⌘K
LIVE
← All companies

LQDA Liquidia (LQDA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001819576
Quote by TradingView
Form 144 · 6
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
229
13F, latest reported quarter
Conversions, 180 days
44
Codes C/M, not in net · $1.1M priced

What the filings say about LQDA

Insiders, 180 days
-$188.8M net sold
1 buyer · 15 sellers · 12% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$16.5M
6 notices

Liquidia insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Liquidia Corp insiders sold a net $188.8M of stock across 332 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Adair Jason
Chief Business Officer
SELL
2026-10-13 SECtraded 2026-10-12
7,301
$207.9K
+28.9%
Context
  • 40 earlier Form 4 trades (code P or S) here by this insider (40 sales), the last on Aug 21, 2026.
  • The trade is 4.1% of the 177,957 shares held after it.
  • 10 other insiders sold within 30 days.
  • 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Adair Jason sold about $207.9K of LQDA under a 10b5-1 plan on Oct 12, 2026; 10 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.
JEFFS ROGER
Chief Executive Officer
SELL
2026-10-13 SECtraded 2026-10-12
32,744
$932.5K
+28.9%
Context
  • 40 earlier Form 4 trades (code P or S) here by this insider (4 buys, 36 sales), the last on Jul 13, 2026.
  • +47.1% median (+51.1% mean) 90-day return after 4 previous buys.
  • The trade is 2.9% of the 1,125,848 shares held after it.
  • 10 other insiders sold within 30 days.
  • 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer JEFFS ROGER sold about $932.5K of LQDA under a 10b5-1 plan on Oct 12, 2026; 10 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.
Boyle Dana
Chief Accounting Officer
SELL
2026-10-13 SECtraded 2026-10-12
5,892
$167.8K
+28.9%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jul 27, 2026.
  • The trade is 3.6% of the 165,609 shares held after it.
  • 10 other insiders sold within 30 days.
  • 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Boyle Dana sold about $167.8K of LQDA under a 10b5-1 plan on Oct 12, 2026; 10 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.
Kaseta Michael
CFO and COO
SELL
2026-10-13 SECtraded 2026-10-12
18,938
$539.4K
+28.9%
Context
  • 34 earlier Form 4 trades (code P or S) here by this insider (4 buys, 30 sales), the last on Jul 13, 2026.
  • +6.9% median (+27.1% mean) 90-day return after 3 previous buys.
  • The trade is 5.6% of the 340,148 shares held after it.
  • 10 other insiders sold within 30 days.
  • 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO and COO Kaseta Michael sold about $539.4K of LQDA under a 10b5-1 plan on Oct 12, 2026; 10 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.
Khindri Sanjeev
Chief Development Officer
SELL
2026-10-13 SECtraded 2026-10-12
1,101
$31.4K
+28.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 13, 2026.
  • The trade is 1.7% of the 64,846 shares held after it.
  • 10 other insiders sold within 30 days.
  • 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Khindri Sanjeev sold about $31.4K of LQDA under a 10b5-1 plan on Oct 12, 2026; 10 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.
332 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 327 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$188.8M over 180 days
-$25.7M over 90 days
below 98% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
229 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
+1031.2% year over year
more than 96% of Pharma & Biotech
Margin
-43.5% net margin
more than 51% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
19.4% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
more than 83% of Pharma & Biotech
What changed in the last 30 days
Oct 13Chief Executive Officer JEFFS ROGER sold $932.5K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13CFO and COO Kaseta Michael sold $539.4K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13General Counsel Schundler Russell sold $389.9K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13Chief Medical Officer Saggar Rajeev sold $262.5K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7Director Bloch Stephen M sold $6.4M (Oct 5)

Watch LQDA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+98.6%12M
+0%+104%+209%+313%2025-102025-122026-022026-042026-062026-082026-10 2026-07-23 · Bloch Stephen M sold $8.6M2026-06-12 · Bloch Stephen M sold $7.0M2026-06-08 · Bloch Stephen M sold $6.9M2026-06-10 · Bloch Stephen M sold $6.8M2026-06-11 · Bloch Stephen M sold $6.6M2026-10-05 · Bloch Stephen M sold $6.4M2026-06-11 · Bloch Stephen M sold $6.0M2026-07-21 · Bloch Stephen M sold $6.0M2026-06-15 · Bloch Stephen M sold $5.9M2026-05-11 · Bloch Stephen M sold $5.7M2026-06-04 · Manning Paul B sold $5.7M2026-04-09 · Kaseta Michael sold $5.4M2026-06-22 · Bloch Stephen M sold $5.3M2026-06-04 · Manning Paul B sold $4.4M2026-07-22 · Bloch Stephen M sold $4.3M2026-06-09 · Bloch Stephen M sold $4.1M2026-05-11 · Bloch Stephen M sold $3.9M2026-08-19 · Saggar Rajeev sold $3.7M2026-05-11 · Bloch Stephen M sold $3.7M2026-04-15 · Kaseta Michael sold $3.5M2026-07-22 · Bloch Stephen M sold $3.3M2026-06-04 · Bloch Stephen M sold $3.0M2026-08-21 · Adair Jason sold $2.9M2026-03-09 · Moomaw Scott sold $2.8M2026-08-19 · Rielly-Gauvin Katherine sold $2.8M2026-06-08 · Bloch Stephen M sold $2.6M2026-01-12 · JEFFS ROGER sold $2.5M2026-07-13 · JEFFS ROGER sold $2.3M2026-06-22 · Bloch Stephen M sold $2.3M2026-06-04 · Bloch Stephen M sold $2.3M2026-08-17 · Saggar Rajeev sold $2.3M2026-07-07 · Bloch Stephen M sold $2.2M2026-08-21 · Adair Jason sold $2.2M2026-07-06 · Bloch Stephen M sold $2.0M2026-07-01 · Bloch Stephen M sold $1.9M2026-06-10 · Bloch Stephen M sold $1.9M2026-07-07 · Bloch Stephen M sold $1.8M2025-11-05 · Saggar Rajeev sold $1.8M2026-05-21 · SINGH RAMAN sold $1.8M2026-04-15 · Kaseta Michael sold $1.7M2026-06-11 · Bloch Stephen M sold $1.7M2026-05-22 · JEFFS ROGER sold $1.5M2026-09-14 · RAMANDEEP SINGH filed to sell $560.2K2026-09-11 · RAMANDEEP SINGH filed to sell $619.2K2026-08-21 · JASON ADAIR filed to sell $5.2M2026-08-19 · RAJEEV SAGGAR filed to sell $3.7M2026-08-19 · Katherine T. Rielly-Gauvin filed to sell $4.1M2026-08-17 · RAJEEV SAGGAR filed to sell $2.3M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LQDA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
10,788,586 sh
$860.2M
FARALLON CAPITAL MANAGEMENT, L.L.C.
8,365,038 sh
$666.9M
Caligan Partners LP
8,118,892 sh
$647.3M
FINDELL CAPITAL MANAGEMENT LLC
3,502,112 sh
$279.2M
VANGUARD CAPITAL MANAGEMENT LLC
3,139,183 sh
$250.3M

Congress trades in LQDA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LQDA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
RAMANDEEP SINGH
Filed 2026-09-14
$560.2K
RAMANDEEP SINGH
Filed 2026-09-11
$619.2K
JASON ADAIR
Filed 2026-08-21
$5.2M
RAJEEV SAGGAR
Filed 2026-08-19
$3.7M
Katherine T. Rielly-Gauvin
Filed 2026-08-19
$4.1M

LQDA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
CapForce IBD Breakout Opportunities ETF
$632.3K position · as of 2026-07-31
3.9%
Invesco Pharmaceuticals ETF
$17.3M position · as of 2026-07-31
3.7%
CapForce IBD 50 ETF
$2.7M position · as of 2026-07-31
3.4%
Invesco Dorsey Wright Healthcare Momentum ETF
$7.1M position · as of 2026-07-31
3.0%
Pacer US Small Cap Cash Cows Growth Leaders ETF
$818.8K position · as of 2026-07-31
2.7%
Alpha Architect U.S. Quantitative Momentum ETF
$8.8M position · as of 2026-06-30
2.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $188.8M sold by insiders over 180 days, 229 funds added last quarter, $16.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LQDA financials

Revenue growth
+1031.2%
XBRL, annual
Net margin
-43.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$450.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+30.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$150.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.10x
long-term 2022-12-31 (42 months older than the period end) plus current 2020-12-31 (66 months older than the period end); equity 2026-06-30
Cash flow to debt
8.44x
TTM operating cash flow over long-term 2022-12-31 (42 months older than the period end) plus current 2020-12-31 (66 months older than the period end)
Return on equity
+131.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+35.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+65.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
31.47x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$3.7B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2022-12-31 (42 months older than the period end) plus current 2020-12-31 (66 months older than the period end), minus cash 2026-06-30
FCF yield
+3.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$158.3M$14.0M$17.5M$15.9M
Operating income-$51.4M-$121.3M-$73.4M-$38.8M
Net income-$68.9M-$130.4M-$78.5M-$41.0M
EPS (diluted)-0.80-1.63-1.21-0.67
Operating cash flow-$35.7M-$93.4M-$41.6M-$28.6M
Cash$190.7M$176.5M$83.7M$93.3M
Long-term debtn/an/an/a$19.9M
SEC XBRL, fiscal years, as known on 2026-10-28

LQDA Stock Sonar score 6/7 axes

Find similar shapesCompare

LQDA ranks highest on profitability (97th percentile) and growth (96th), and lowest on risk and compliance (14th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
97
Inputs
  • Return on equity+131.8% · 97 pct, sector of 545
  • Return on assets+35.6% · 95 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+65.9% · 99 pct, sector of 576
Financial health
75
Inputs
  • Debt to equity0.10x · 54 pct, sector of 352
  • Cash flow to debt8.44x · 96 pct, sector of 371
Growth
96
Inputs
  • Revenue growth, YoY+1031% · 96 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
29
Inputs
  • Net Form 4 buying (codes P and S), 180d-$176.7M · 2 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
92
Inputs
  • Funds adding, latest quarter229 · 92 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
14
Inputs
  • Short interest, % of float+19.4% · 16 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+24.4% · 11 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LQDA filings, in plain words

Are Liquidia insiders buying or selling LQDA?

In the 180 days to 2026-10-28, Liquidia insiders were net sellers, a net $188.8M: $317.9K of purchases and $189.1M of sales reported on Form 4, by 1 buyer and 15 sellers.

Are there planned insider sales of LQDA?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $16.5M of stock; the latest, by RAMANDEEP SINGH, was filed 2026-09-14.

Read the full summary

In the 180 days to 2026-10-28, Liquidia insiders were net sellers of LQDA, a net $188.8M across purchases and sales reported on Form 4 by 1 buyer and 15 sellers. Sales outweighed purchases more than tenfold by value. 12% of the 113 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $16.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies